+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Glioblastoma Multiforme Treatment (GBM): Global Strategic Business Report

  • PDF Icon

    Report

  • 192 Pages
  • February 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309886

Global Glioblastoma Multiforme Treatment (GBM) Market to Reach $4.3 Billion by 2030

The global market for Glioblastoma Multiforme Treatment (GBM) estimated at US$2.4 Billion in the year 2022, is projected to reach a revised size of US$4.3 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2022-2030. Radiation Therapy, one of the segments analyzed in the report, is projected to record 7.2% CAGR and reach US$1.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Surgery segment is readjusted to a revised 8.8% CAGR for the next 8-year period.

The U.S. Market is Estimated at $713.5 Million, While China is Forecast to Grow at 7% CAGR

The Glioblastoma Multiforme Treatment (GBM) market in the U.S. is estimated at US$713.5 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$741.3 Million by the year 2030 trailing a CAGR of 7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.5% and 6.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.

Select Competitors (Total 33 Featured) -

  • Amneal Pharmaceuticals, Inc.
  • CARsgen Therapeutics
  • Epitopoietic Research Corporation (ERC.SA.)
  • F. Hoffmann-La Roche AG
  • GBM Communications
  • GBM Digital Technologies
  • ImmunoCellular Therapeutics Ltd.
  • Ivy Foundation
  • Sapience Therapeutics
  • SonALAsense

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and the publisher's Research Platform
  • Complimentary updates for one year

Frequently Asked Questions about the Global Market for Glioblastoma Multiforme Treatment (GBM)

What is the estimated value of the Global Market for Glioblastoma Multiforme Treatment (GBM)?

The Global Market for Glioblastoma Multiforme Treatment (GBM) was estimated to be valued at $2.4 Billion in 2022.

What is the growth rate of the Global Market for Glioblastoma Multiforme Treatment (GBM)?

The growth rate of the Global Market for Glioblastoma Multiforme Treatment (GBM) is 7.6%, with an estimated value of $4.3 Billion by 2030.

What is the forecasted size of the Global Market for Glioblastoma Multiforme Treatment (GBM)?

The Global Market for Glioblastoma Multiforme Treatment (GBM) is estimated to be worth $4.3 Billion by 2030.

Who are the key companies in the Global Market for Glioblastoma Multiforme Treatment (GBM)?

Key companies in the Global Market for Glioblastoma Multiforme Treatment (GBM) include Amneal Pharmaceuticals, Inc., CARsgen Therapeutics, Epitopoietic Research Corporation (ERC.SA.), F. Hoffmann, La Roche AG, GBM Communications, GBM Digital Technologies, ImmunoCellular Therapeutics Ltd., Ivy Foundation and Sapience Therapeutics.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Glioblastoma Multiforme Treatment (GBM) - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Glioblastoma Multiforme Treatment (GBM) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 3: World Historic Review for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 4: World 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 6: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 7: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 9: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 10: World 16-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 12: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 13: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 15: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 16: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Tumor Treating Field (TTF) Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 18: World Historic Review for Tumor Treating Field (TTF) Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 19: World 16-Year Perspective for Tumor Treating Field (TTF) Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 21: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 22: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 24: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 25: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 26: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 27: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 28: World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 29: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 30: World Historic Review for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 31: World 16-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 32: USA Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 33: USA Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 34: USA 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
  • Table 35: USA Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 36: USA Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 37: USA 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
  • CANADA
  • Table 38: Canada Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 39: Canada Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 40: Canada 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
  • Table 41: Canada Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 42: Canada Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 43: Canada 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
  • JAPAN
  • Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 44: Japan Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 45: Japan Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 46: Japan 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
  • Table 47: Japan Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 48: Japan Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 49: Japan 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
  • CHINA
  • Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 50: China Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 51: China Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 52: China 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
  • Table 53: China Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 54: China Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 55: China 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
  • EUROPE
  • Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 56: Europe Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 57: Europe Historic Review for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 58: Europe 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
  • Table 59: Europe Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 60: Europe Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 61: Europe 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
  • Table 62: Europe Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 63: Europe Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 64: Europe 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
  • FRANCE
  • Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 65: France Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 66: France Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 67: France 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
  • Table 68: France Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 69: France Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 70: France 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
  • GERMANY
  • Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 71: Germany Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 72: Germany Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 73: Germany 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
  • Table 74: Germany Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 75: Germany Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 76: Germany 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
  • ITALY
  • Table 77: Italy Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 78: Italy Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 79: Italy 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
  • Table 80: Italy Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 81: Italy Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 82: Italy 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
  • Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 83: UK Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 84: UK Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 85: UK 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
  • Table 86: UK Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 87: UK Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 88: UK 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
  • REST OF EUROPE
  • Table 89: Rest of Europe Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 90: Rest of Europe Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 91: Rest of Europe 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
  • Table 92: Rest of Europe Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 93: Rest of Europe Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 94: Rest of Europe 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
  • Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 95: Asia-Pacific Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 96: Asia-Pacific Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 97: Asia-Pacific 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
  • Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 99: Asia-Pacific Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 100: Asia-Pacific 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
  • REST OF WORLD
  • Table 101: Rest of World Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 102: Rest of World Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 103: Rest of World 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
  • Table 104: Rest of World Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 105: Rest of World Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 106: Rest of World 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Amneal Pharmaceuticals, Inc.
  • CARsgen Therapeutics
  • Epitopoietic Research Corporation (ERC.SA.)
  • F. Hoffmann-La Roche AG
  • GBM Communications
  • GBM Digital Technologies
  • ImmunoCellular Therapeutics Ltd.
  • Ivy Foundation
  • Sapience Therapeutics
  • SonALAsense